Neuronetics (FRA:NRC) LT-Debt-to-Total-Asset: 0.64 (As of Mar. 2026)

What is Neuronetics LT-Debt-to-Total-Asset?

Neuronetics FRA:NRC +2.58% 57 LT-Debt-to-Total-Asset is 0.64 as of Mar. 2026. GuruFocus rates FRA:NRC with a GF Score™ of 57/100 and a GF Value™ of €1.53 (Modestly Undervalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Neuronetics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.64.

Neuronetics's long-term debt to total assets ratio increased from Mar. 2025 (0.55) to Mar. 2026 (0.64). It may suggest that Neuronetics is progressively becoming more dependent on debt to grow their business.

Neuronetics (FRA:NRC) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Neuronetics LT-Debt-to-Total-Asset Related Terms

Neuronetics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Neuronetics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuronetics LT-Debt-to-Total-Asset Chart

Neuronetics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.28

0.22

0.53

0.55

0.60

Neuronetics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.55	0.56	0.59	0.60	0.64

57GF Score

Neuronetics Inc FRA:NRC

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Neuronetics LT-Debt-to-Total-Asset Calculation

Neuronetics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	72.37	/	120.885
	=	0.60

Neuronetics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	69.171	/	108.506
	=	0.64

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.64 mean?

Neuronetics (FRA:NRC) has a LT-Debt-to-Total-Asset of 0.64 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Neuronetics and its competitors.

Is Neuronetics' LT-Debt-to-Total-Asset too high?

Neuronetics' current LT-Debt-to-Total-Asset is 0.64. Overall, Neuronetics has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Neuronetics' LT-Debt-to-Total-Asset compare to ZOMDF and OM?

Neuronetics' LT-Debt-to-Total-Asset of 0.64 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Neuronetics and its competitors. Neuronetics's current LT-Debt-to-Total-Asset is 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Neuronetics stock overvalued right now?

Based on GuruFocus' analysis, Neuronetics (FRA:NRC) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.53, compared to a current price of €1.20 — trading 21.9% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.64. Neuronetics' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Neuronetics (FRA:NRC), the current LT-Debt-to-Total-Asset is 0.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuronetics (FRA:NRC) Overvalued in 2026?

Based on GuruFocus' analysis, Neuronetics stock appears to be undervalued. The current stock price of €1.20 is trading 21.9% below its estimated GF Value™ of €1.53. GuruFocus considers Neuronetics to be Modestly Undervalued.

Key valuation signals for FRA:NRC:

LT-Debt-to-Total-Asset: 0.64
GF Value™: €1.53 vs. price of €1.20 (21.9% below fair value)
GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the FRA:NRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuronetics Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ZOMDF OM RPID NNOX RTGN SNWV LNSR SERA ECOR RCEL ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges STIM:USA

Address 3222 Phoenixville Pike, Malvern, PA, USA, 19355

Website https://www.neurostar.com

Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.

57GF Score

Get the complete analysis for FRA:NRC

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.20

Price

€1.53

GF Value

View FRA:NRC Analysis

See LT-Debt-to-Total-Asset data for all stocks →